Entera Bio Announces Positive Feedback and Guidance from the US FDA Regarding its Development Plans for Oral PTH in Osteoporosis
JERUSALEM, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration (FDA) to discuss the Company’s development plan for Oral PTH for the …